Skip to main content

Table 3 Median TTP and OS by treatment arm.

From: A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

  Treatment Group  
  DC
(n = 67)
D
(n = 65)
 
Median PFS (mo) 3.33 2.60 P = 0.012
(Log-Rank test)
Min - Max 0.2 - 23.0 0.5 - 17.8  
95% CI (2.59 - 4.07) (1.74 - 3.46)  
1-year with no progression 11.6% 5.4%  
Median survival (months) 10.27 7.70 P = 0.550
(Log-Rank test)
Min - Max 0.7 - 36.8 0.5 - 43.2  
95% CI (7.07 - 13.47) (3.39 - 12.01)  
1-year survival Kaplan-Meier estimate (%) 43.8% 40.3%